Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 Aug 2022
Historique:
received: 22 06 2022
revised: 01 08 2022
accepted: 02 08 2022
entrez: 12 8 2022
pubmed: 13 8 2022
medline: 16 8 2022
Statut: epublish

Résumé

The vast amount of epidemiologic and genomic data that were gathered as a global response to the COVID-19 pandemic that was caused by SARS-CoV-2 offer a unique opportunity to shed light on the structural evolution of coronaviruses and in particular on the spike (S) glycoprotein, which mediates virus entry into the host cell by binding to the human ACE2 receptor. Herein, we carry out an investigation into the dynamic properties of the S glycoprotein, focusing on the much more transmissible Delta and Omicron variants. Notwithstanding the great number of mutations that have accumulated, particularly in the Omicron S glycoprotein, our data clearly showed the conservation of some structural and dynamic elements, such as the global motion of the receptor binding domain (RBD). However, our studies also revealed structural and dynamic alterations that were concentrated in the aa 627-635 region, on a small region of the receptor binding motif (aa 483-485), and the so-called "fusion-peptide proximal region". In particular, these last two S regions are known to be involved in the human receptor ACE2 recognition and membrane fusion. Our structural evidence, therefore, is likely involved in the observed different transmissibility of these S mutants. Finally, we highlighted the role of glycans in the increased RBD flexibility of the monomer in the up conformation of Omicron.

Identifiants

pubmed: 35955815
pii: ijms23158680
doi: 10.3390/ijms23158680
pmc: PMC9369368
pii:
doi:

Substances chimiques

Glycoproteins 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : EU
ID : H2020-SC1-PHE-CORONAVIRUS-2020
Organisme : Ministry of Education, Universities and Research
ID : Departments of Excellence-2018' Program (Dipartimenti di Eccellenza) to DIBAF-Department of University of Tuscia, Project 'Landscape 4.0-food, wellbeing and environment'.
Organisme : Ministero della Salute, 5 per Mille
ID : Project 5M-2020-23682104

Références

J Comput Chem. 2005 Dec;26(16):1701-18
pubmed: 16211538
Euro Surveill. 2022 Feb;27(5):
pubmed: 35115077
J Med Virol. 2022 Jul;94(7):3192-3202
pubmed: 35307848
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Nature. 2021 Jun;594(7861):19-20
pubmed: 34031583
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374797
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
Nature. 2022 Feb;602(7895):26-28
pubmed: 35091701
BMC Bioinformatics. 2020 Aug 21;21(Suppl 10):352
pubmed: 32838759
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Clin Infect Dis. 2022 Jun 10;74(11):2057-2060
pubmed: 34471930
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
pubmed: 8744570
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Chem Theory Comput. 2015 Aug 11;11(8):3696-713
pubmed: 26574453
Curr Opin Struct Biol. 2022 May 19;75:102402
pubmed: 35717706
Proteins. 1993 Dec;17(4):412-25
pubmed: 8108382
Int J Mol Sci. 2021 May 22;22(11):
pubmed: 34067272
Science. 2021 Jan 29;371(6528):466-467
pubmed: 33510015
Traffic. 2016 Jun;17(6):593-614
pubmed: 26935856
J Chem Theory Comput. 2013 Jul 9;9(7):3084-95
pubmed: 26583988
J Chem Theory Comput. 2008 Jan;4(1):116-22
pubmed: 26619985
Science. 2020 Sep 25;369(6511):1586-1592
pubmed: 32694201
Front Med (Lausanne). 2022 Jan 20;8:815870
pubmed: 35127770
Clin Infect Dis. 2022 Mar 10;:
pubmed: 35271704
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
Lancet Infect Dis. 2022 May;22(5):622-635
pubmed: 34953520
Chem Sci. 2021 Nov 25;13(2):386-395
pubmed: 35126971
Nat Chem. 2021 Oct;13(10):963-968
pubmed: 34413500
J Chem Phys. 2007 Jan 7;126(1):014101
pubmed: 17212484
Ann Med. 2022 Dec;54(1):524-540
pubmed: 35132910
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Comput Chem. 2008 Mar;29(4):622-55
pubmed: 17849372

Auteurs

Ingrid Guarnetti Prandi (IG)

Department for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.

Carla Mavian (C)

Emerging Pathogen Institute, University of Florida, Gainesville, FL 32608, USA.
Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.

Emanuela Giombini (E)

Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy.

Cesare E M Gruber (CEM)

Laboratory of Virology, INMI Lazzaro Spallanzani IRCCS, Via Portuense 292, 00149 Roma, Italy.

Daniele Pietrucci (D)

Department for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.
Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies-IBIOM, CNR, 70126 Bari, Italy.

Stefano Borocci (S)

Department for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.
Institute for Biological Systems-ISB, CNR, Area della Ricerca di Roma 1, SP35d 9, 00010 Montelibretti, Italy.

Nabil Abid (N)

Laboratory of Transmissible Diseases and Biological Active Substances LR99ES27, Faculty of Pharmacy, University of Monastir, Rue Ibn Sina, Monastir 5000, Tunisia.
High Institute of Biotechnology of Monastir, Department of Molecular and Cellular Biology, University of Monastir, Monastir 5000, Tunisia.

Andrea R Beccari (AR)

Dompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.

Carmine Talarico (C)

Dompé Farmaceutici SpA, Via Campo di Pile, 67100 L'Aquila, Italy.

Giovanni Chillemi (G)

Department for Innovation in Biological, Agro-Food and Forest Systems-DIBAF, University of Tuscia, Via S. Camillo de Lellis s.n.c., 01100 Viterbo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH